Armour Thyroid
Phase 3Small molecule
AbbVieArmour Thyroid is one of 8 small molecule programs targeting Hypothyroidism. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hypothyroidism
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tricor
JJagotec
Approved
Levothyroxin
BBerlin-Chemie AG Menarini Group
Phase 3
Armour Thyroid
AbbViePhase 3
Triostat
VViking Therapeutics, Inc.
Preclinical
Medication
NNYU Langone Health
Preclinical
Thyrotropin-Releasing Hormone
NNational Center for Research Resources (NCRR)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Armour Thyroid. EMBL-EBI & Wellcome Sanger Institute.
- [4]